Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon

por Khan, Shaheen, von Itzstein, Mitchell S., Lu, Rong, Bermas, Bonnie L., Karp, David R., Khan, Saad A., Fattah, Farjana J., Park, Jason Y., Saltarski, Jessica M., Gloria‐McCutchen, Yvonne, Xie, Yang, Li, Quan‐Zhen, Wakeland, Edward K., Gerber, David E.
Publicado 2020

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors

por Ahmed, Murtaza, von Itzstein, Mitchell S, Sheffield, Thomas, Khan, Shaheen, Fattah, Farjana, Park, Jason Y, Popat, Vinita, Saltarski, Jessica M, Gloria-McCutchen, Yvonne, Hsiehchen, David, Ostmeyer, Jared, Khan, Saad A, Sultana, Nazima, Xie, Yang, Li, Quan-Zhen, Wakeland, Edward K, Gerber, David E
Publicado 2021

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

por von Itzstein, Mitchell S., Gonugunta, Amrit S., Sheffield, Thomas, Homsi, Jade, Dowell, Jonathan E., Koh, Andrew Y., Raj, Prithvi, Fattah, Farjana, Wang, Yiqing, Basava, Vijay S., Khan, Shaheen, Park, Jason Y., Popat, Vinita, Saltarski, Jessica M., Gloria-McCutchen, Yvonne, Hsiehchen, David, Ostmeyer, Jared, Xie, Yang, Li, Quan-Zhen, Wakeland, Edward K., Gerber, David E.
Publicado 2022